Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes.

The addition of EB1089 together with ixazomib presented a trend towards decreased expression of myogenin compared to ixazomib treatment alone, but the results did not reach statistical significance.

also in 111,027 other papers

Treatment with oprozomib at 24 h showed a trend towards an increase in myogenin expression (Fig. 3 a-b).

also in 53,322 other papers